General Drug Use-Result Study of Evusheld Intramuscular Injection Set (Treatment and Prevention of Symptomatic Disease Caused by SARS-CoV-2 Infection)
Latest Information Update: 27 May 2025
At a glance
- Drugs Cilgavimab/tixagevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 28 Jan 2025 Status changed from recruiting to completed.
- 11 Jan 2024 Planned End Date changed from 31 Mar 2025 to 31 Mar 2026.
- 11 Jan 2024 Planned primary completion date changed from 31 Mar 2025 to 31 Mar 2026.